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Abstract
Background: SPARC is a matricellular protein involved in tissue remodelling, cell migration and angiogenesis, while
forkhead box P3 (FOXP3) protein functions as a transcription factor involved in immune cell regulation. Both SPARC and
FOXP3 can play an anti-tumorigenic role in cancer progression. The aim was to determine if SPARC, FOXP3, CD8 and
CD45RO expression levels are associated with colorectal cancer (CRC) stage, disease outcome and long-term cancer-specific
survival (CSS) in stage II and III CRC.
Methods and Findings: SPARC expression was initially assessed in 120 paired normal and stage I-IV CRCs. Subsequently,
approximately 1000 paired patient samples of stage II or III CRCs in tissue microarrays were stained for SPARC, FOXP3, CD8
or CD45RO. Proportional hazards modelling assessed correlations between these markers and clinicopathological data,
including disease outcome and cancer specific survival (CSS). Both SPARC and FOXP3 expression were significantly greater
in CRC than normal colon (p,0.0001). High SPARC expression correlated with good disease outcome ($60 mths without
disease recurrence, p=0.0039) and better long-term CSS in stage II CRC (,0.0001). In stage III CRC, high SPARC expression
correlated with better long-term CSS (p,0.0001) and less adjuvant chemotherapy use (p=0.01). High FOXP3 correlated
with a good disease outcome, better long-term CSS and less adjuvant chemotherapy use in stage II (p,0.0037, ,0.0001
and p=0.04 respectively), but not in stage III CRC. High CD8 and CD45RO expression correlated with better disease
outcome in stage II CRC, and better CSS, but the differences were not as marked as for SPARC and FOXP3.
Conclusions: These data suggest that high SPARC and FOXP3 are associated with better disease outcome in stage II CRC
and may be prognostic indicators of CSS. Further assessment of whether these markers predict patients at high risk of
recurrence with stage II CRC and functional studies of these effects are underway
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Introduction
Colorectal cancer (CRC) is highly prevalent in western
populations and one of the leading causes of cancer morbidity
and mortality worldwide[1,2]. Excluding non-melanoma skin
cancer, CRC is the most common cancer in Australia and the
second most common cause of death due to malignant
disease[3,4]. The American Joint Committee on Cancer (AJCC)
developed a commonly used staging system to determine patient
prognosis. There is, however, overlap in the 5-year survival rates
between stages II and III CRC[5,6]. Stage III cancers have
demonstrated lymphatic spread whilst stage II cancers have
tumours localised to the intestinal mucosa. Some of the stage II
tumours, however, may also have micrometastases that go
undetected. In view of this, consideration of the biological
characteristics of the tumour, through the identification of
biomarkers that predict disease extent, may provide a more
accurate means of correlating cancer stage with disease outcome,
and allow application of the most appropriate treatments for
individual patients.
Tumour infiltrating T lymphocytes that express CD8 and
CD45RO have been shown to correlate with better CRC
outcomes[7,8,9,10]. The presence of a high density of CD8
+ T
cells is also associated with the absence of tumour invasion, an
earlier disease stage and improved patient survival[11,12]. High
CD45RO
+ T cell densities in lymph node metastasis and tumours
of CRC also associate with less tumour invasiveness, lower disease
stage and a better patient survival[9,12]. Two further potential
biomarkers of interest in the pathogenesis and prognosis of CRC
are Secreted Protein Acidic and Rich in Cysteine (SPARC) and
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26forkhead box P3 (FOXP3) as they are also both highly expressed in
malignant diseases and have been demonstrated to significantly
correlate with disease outcome.
SPARC is a matricellular glycoprotein that is involved in tissue
remodelling, wound repair, cell migration and angiogene-
sis[13,14,15,16]. It is expressed in numerous tissues, especially in
damaged tissues where extracellular matrix (ECM) remodelling is
necessary in response to injury[17]. High SPARC expression has
been associated with enhanced tumour growth, metastasis and
poor disease prognosis in various malignancies including melano-
ma, breast and oesophageal cancers[6,18,19]. SPARC has also
been implicated in colonic polyp development and CRC tumour
progression through the regulation of cycloxygenase-2 (COX-
2)[20] and transforming growth factor beta-1 (TGFb-1)[21].
These are involved in regulation, and breakdown, of the ECM
surrounding tumour cells. In ovarian cancers, however, high
SPARC expression levels are associated with a good progno-
sis[22]. This correlation is a result of SPARC’s ability to down-
regulate macrophage recruitment to the tumour site and the
production and activity of interleukin (IL)-6, prostanoids and
matrix metalloproteinases to decrease the associated inflamma-
tion[23].
FOXP3 is also a biological marker of interest and is the key
transcription factor controlling regulatory T cell (Treg) develop-
ment and function. Tregs suppress the activation of the immune
system, thereby maintaining immune system homeostasis and
tolerance to self-antigens. In doing so, however, these cells can
suppress the anti-tumour immunological response by reducing
cytotoxic T cell activity by direct cell-to-cell contact, or through
the release of cytokines[24]. A direct link between the presence of
Tregs and the progression of ovarian cancer has been demon-
strated, where tumour FOXP3+ Tregs suppressed tumour specific
immunity and contributed to reduced survival[25]. In breast
cancer, an increase in the Treg population, both in peripheral
blood and tumour tissue, was also reported and a recent study
demonstrated a correlation between intratumoural infiltration of
FOXP3+ Tregs in breast cancer and the risk of late relapse[26].
Given the central contribution of FOXP3 to Treg function, the
expression of FOXP3 by tumour cells may represent a novel
mechanism by which cancers suppress the immune system to
escape destruction.
In this study we investigated SPARC and FOXP3 in stage II
and III CRC tissue and compare their prognostic value against the
known CRC prognostic markers CD8 and CD45RO that are
expressed by tumour infiltrating T lymphocytes. These have been
shown to correlate with a better CRC disease outcome[7,8,9,10].
The presence of a high density of CD8
+ T cells is associated with
the absence of tumour invasion, an earlier disease stage and
improved patient survival[11,12].
The aims of this study were to determine if SPARC and FOXP3
expression levels are associated with CRC stage, disease outcome
and long-term cancer-specific survival in stage II and III CRC and
to compared the prognostic value of these two markers against the
known prognostic CRC markers CD8 and CD45RO.
Materials and Methods
Ethics statement
Ethical approval for this research was obtained from the Human
Research Ethics Committee of the Southern Metropolitan Area
Health Services and from the Sir Charles Gairdner Hospital Human
Research Ethics Committee. All patients providing tissue for the
tissue microarray signed a consent form prior to surgical removal of
the intestinal cancer to allow for this research to be undertaken.
Patient details
Demographic information was collected retrospectively on all
patients from pathology records, and information on disease-
specific survival was obtained from the Cancer Registry of
Western Australia. All patients had a minimum follow-up of 60
months or until death. Information on the use of adjuvant
chemotherapy with fluorouracil/leucovorin-based regimens fol-
lowing surgery was obtained from hospital medical records.
Patients were considered to have had a good disease outcome if
there was no disease recurrence within 60 months of diagnosis,
while patients who had disease recurrence within 60 months of
diagnosis, or had died from their disease, were considered to have
had a poor disease outcome.
Initial SPARC assessment
SPARC levels were initially assessed in histological sections of
AJCC stage I to IV CRC tissue to determine if there was an
association with CRC and in which cells SPARC was expressed.
This included samples (n=120) collected from a 464 patient
cohort diagnosed with CRC between 1996 and 2002.
Tissue microarray (TMA)
Construction of the TMAs used in this study has previously
been described[27]. The TMAs consisted of approximately 1000
cases each of stage II and III CRC archival tissue samples from
patients who were diagnosed with CRC during the period of 1990
to 1999 at the Sir Charles Gairdner Hospital. Each case consisted
of two 1mm diameter tumour tissue cores and an additional 1mm
diameter core taken from histologically normal colon mucosa.
Assessment of SPARC expression was undertaken on 233
patients with AJCC stage II and 125 AJCC stage III CRCs. T cell
density analysis of FOXP3, CD8 and CD45RO was derived from
a larger patient cohort of the same archived AJCC stage II and III
CRC samples that has previously been described[28].
Four micrometer thick formalin-fixed paraffin embedded
sections from the TMAs had high temperature antigen retrieval
with 1 mM EDTA (pH 8) and 10 mM citrate buffer (pH 6). Non-
specific staining was blocked. Primary antibodies anti-SPARC
(1:200; Hematologic Technologies Inc, Vermont, USA), anti-CD8
(clone C8/144B, ready to use; DakoCytomation, Heverlee,
Belgium), CD45RO (clone UCHL1, ready to use; DakoCytoma-
tion) and anti-FOXP3 (1:100; Abcam, Cambridge, MA, USA)
were used with an overnight incubation at 4uC. After washing, the
sections were incubated with 1:2 diluted biotinylated link universal
antibody and streptadvidin-HRP solutions (Universal LSAB+ kit,
DakoCytomation Carpinteria, CA) for 30 minutes each. Colour
was developed by incubating in 3,3-diaminobenzidine (DAB)
solution (Substrate Chromogen System, DakoCytomation, Car-
pinteria, CA) and sections were counterstained with Mayers
haemotoxylin and coverslipped with Depex. Staining without
primary antibody was used as a negative control. Pictures were
taken using a digital camera (Nikon DS-L1) in bright field on an
inverted microscope (Nikon TE2000-U). Tissue microarrays were
scanned using the Aperio ScanScope XT Digital Slide Scanner
(Aperio Technologies, CA) located at the Australian Microscopy &
Microanalysis Research Facility at the Centre for Microscopy,
Characterisation & Analysis, The University of Western Australia
Assessment of SPARC expression
The role of SPARC in the pathogenesis of different tumours is
highly contextual. In both CRC, and normal colonic tissue,
SPARC was noted to be almost exclusively expressed by vimentin-
positive stromal mesenchymal cells. Its expression was not
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number of normal epithelial cells. SPARC expression within
malignant and control tissue, therefore, needed to be controlled for
the amount of stromal tissue present. Serial tissue sections were
taken and stained for SPARC and the specific mesenchymal cell
marker, vimentin (anti-vimentin; 1:30; Novocastra Laboratories
Ltd). The vimentin-positive cells were morphologically identified
by an independent histopathologist as stromal mesenchymal cells.
SPARC positive areas were determined using a positive pixel
count algorithm (ImageScope v8.0, Aperio Technologies, CA),
which measures the staining intensity of the positive, strong-
positive and negative pixels (Figure 1). SPARC expression was
only measured in regions containing vimentin-positive cells and
the ratio of SPARC to vimentin staining for each TMA core was
used to control for the stromal tissue content within each sample.
All SPARC results are presented as a ratio of SPARC to vimentin.
Assessment of FOXP3, CD8 and CD45RO expression
The measurement of T-cell density has been previously
reported[28] and used image analysis software (Imagescope v8.0,
Aperio) to evaluate the number of FOXP, CD8 and CD45RO
positive cells (cells per square millimetre). Individual cores were
examined and annotated to ensure that only normal colonic
epithelium or viable tumour tissue was included in the area of
analysis.
Statistical analysis
Results were expressed as mean 6 SEM. Student’s unpaired T-
test and Kruskal-Wallis analysis with Dunn’s post tests were used
to compare SPARC expression and T-cell density between the
different groups, and a P value of ,0.05 was considered
statistically significant. SPARC expression and T-cell densities
were classified as high or low in relation to the median value as
shown in Salama et al, 2008[28]. All statistical analyses and graphs
were created using Graphpad PrismH 4.0 software package for
Windows PC (Graphpad Software, San Diego, CA, USA). The
Kaplan-Meier product limit estimate of survival was used to
calculate long-term cancer-specific survival. The event variable
was death from CRC (as defined by coding on the patient’s death
certificate). All survival times were calculated from the date of
histological diagnosis of CRC until either an event occurred or
they remained alive at 1
st March 2008.
Figure 1. Tissue microarray analysis. SPARC and vimentin staining from a single patient. Images demonstrate serial DAB-stained tissue sections
for both (A) SPARC and (C) vimentin and computer analysed images of the respective DAB staining (B and C). Blue represents DAB-negative pixels
(dark areas), orange DAB-positive pixels and red strongly DAB-positive pixels (light areas). SPARC expression was selectively measured only in the
regions of the tissue that were also vimentin-positive.
doi:10.1371/journal.pone.0022047.g001
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Stromal SPARC expression in normal colonic tissue vs.
stage I to IV CRC
SPARC levels were examined in 120 paired normal colonic and
AJCC stages I to IV CRC. SPARC expression was significantly
greater in all cancers compared to the corresponding normal
colonic tissue (Figure 2A). It was also significantly greater in
CRC stages II to IV compared to stage I, however, there were no
differences between stages II to IV (Figure 2B). When patients
with stage II and III CRC were divided into those with a good
outcome (no disease recurrence within 5 years of diagnosis) and a
poor outcome (disease recurrence within 5 years of diagnosis or
death from disease), patients with a good disease outcome in both
stage II and III had higher SPARC expression in the primary
tumour, but these findings were not significantly different
(Figure 2C).
Stromal SPARC expression in stage II and III CRC
TMAs were employed to measure SPARC in a cohort of 358
stage II or III CRC patients. SPARC expression was significantly
greater in all cancer (stage II and III combined) compared to
normal colonic tissue (p,0.0001; Figure 3A), with no statistical
differences detected in SPARC expression between patients with
stage II and III disease (Figure 3B). When patients were further
divided into stage II and III disease with either a good or a poor
outcome, SPARC expression was significantly greater in patients
with a good disease outcome in stage II CRC (p=0.0039;
Figure 3C), however, no statistical difference was observed
between the groups in stage III CRC (Figure 3D).
T-cell FOXP3, CD8 and CD45RO expression in CRC
Examining T cell density using TMAs of a 967 cohort, FOXP3
was significantly higher in CRC tissue compared to normal colonic
mucosa (p,0.002, Figure 4A and Figure 5). In contrast, CD8
and CD45RO expression levels were significantly lower in normal
colonic mucosa (p,0.0001, Figure 4B and C) consistent with
previously findings. When dividing the samples into stages II or
III, FOXP3 was significantly greater in stage II compared to stage
III (p,0.002, Figure 4D). Similarly, CD8 and CD45RO
expression levels were significantly greater in patients with stage
II CRC compared to stage III (p,0.0001 for both, Figure 4E
and F). When comparing these markers with disease outcome,
FOXP3 was significantly greater in patients with a good compared
to poor outcome in stage II CRC (p=0.0037; Figure 6A), whilst
no statistical differences were observed in stage III CRC
(Figure 6B). These results were similar for CD8 and CD45RO
(p=0.0195 and 0.0054 respectively, Figure 6C, D, E and F).
Cancer-specific survival
Patients were followed a minimum of 60 months or until death.
The median follow-up time was 60.6 months for patients with AJCC
Figure 2. Correlation between SPARC expression and AJCC disease staging. (A) Percentage of positively stained cells in AJCC stage I, II, III
and IV CRCs compared to normal colonic tissue (Con). SPARC expression was significantly greater in CRC compared to control. There was a
significantly greater number of SPARC positive cells in stage II, III and IV CRC compared to stage I (p=0.092, p=0.005 and p=0.0007 respectively).
Data presented as a scatter plot with the mean 6 SEM. (B) P values comparing the percentage of SPARC positive cells in stage I, II, III and IV CRC. (C)P
values comparing SPARC expression in stage II to III good and poor outcome CRC. No differences in SPARC levels between good and poor stage II
CRC or good and poor stage III CRC. Data expressed as a percentage of positively stained cells 6 SEM.
doi:10.1371/journal.pone.0022047.g002
SPARC and FOXP3 in Colorectal Cancer
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22047stage II disease and 41.3 months for patients with stage III disease.
The mean SPARC and FOXP3 expression in the primary tumours
of patients with and without disease recurrence at each time point
were measured to determine if the levels correlated with disease
recurrence over time. Stage II CRC patients without disease
recurrence, had significantly higher SPARC levels in their primary
tumours at all time pointsupto 60 months,and for mostpointsupto
138 months, compared to those patients suffering a disease
recurrence (Figure 7A). In stage III CRC, SPARC levels were
significantly higher in patients without disease recurrence 84 months
from diagnosis and onwards (Figure 7B). This association between
high SPARC expression and low disease recurrence was reinforced
by univariate analysis demonstrating that the difference between the
two groups (with, and without, disease recurrence) was significantly
different in both stage II and III (p,0.0001; Figure 7A and B).
Higher FOXP3 levels were also associated with less disease
recurrence in stage II CRC (Figure 7C), and although the
FOXP3 expression levels in the primary tumours were different
between patients with and without disease recurrence in stage III
as various time points (Figure 7D), these differences were not as
marked as in stage II disease. As with SPARC, the overall FOXP3
expression was significantly different between the patients with,
and without, disease recurrence in both stage II and III
(p,0.0001: Figure 7C and D).
Overall survival
By the end of the study period, 27% of patients had died from
CRC and 22% had died from other causes. To assess overall
patient survival, Kaplan-Meier survival curves were derived to
show high and low marker levels in relation to the median SPARC
value, and their association with survival. High SPARC and
FOXP3 levels both significantly correlated with a better long-term
survival (p,0.0001 and 0.0002 respectively; Figure 8A and B).
High CD8 and CD45RO levels also correlated with a better long-
term survival, but compared to SPARC and FOXP3, the
separation between the curves and the significance levels were
not as great (Figure 8C and D). A univariate survival analysis was
used to determine the prognostic significance of each of the four
markers. Table 1A shows that high SPARC, FOXP3, CD8 and
CD45RO expression in CRC tissue all independently predicted
survival. Combining all four markers in a multivariate analysis
(Table 1B) demonstrated, that while each of these markers had
significant prognostic value on their own, used together they did
not improve the prediction of survival. The combination of
SPARC and FOXP3, or SPARC and CD8, however, significantly
predicted survival better than using all four markers in concert, or
the combination of FOXP3, CD8 and CD45RO (Table 1B).
None of these combinations, however, were better at predicting
survival than SPARC used alone.
Figure 3. SPARC expression in stage II and III CRC using TMAs. (A) The SPARC to vimentin ratio was significantly greater in CRC tissue
compared to normal colonic tissue. (B) No difference in SPARC expression was observed between stage II and III CRC. (C) SPARC was significantly
greater in patients with a good disease outcome in stage II CRC, but not in (D) stage III CRC. Each dot represents one patient and the bars represent
the median value 6 SEM.
doi:10.1371/journal.pone.0022047.g003
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was significantly greater in CRC tissue compared to normal colonic tissue, whilst (B) CD8 and (C) CD45RO expression levels were significantly greater
in normal colonic tissue compared to CRC tissue. When looking at T cell density and disease stage (D – FOXP3; E – CD8 and F – CD45RO), the
expression of all three markers were significantly greater in stage II CRC compared to stage III CRC. Each dot represents one patient and the bars
represent the median value 6 SEM.
doi:10.1371/journal.pone.0022047.g004
Figure 5. Representative images of CD8, CD45RO and FOXP3 staining in normal colonic tissue, stage II and III CRC. Images
demonstrate DAB-stained tissue sections for CD8 positive cells, CD45RO-positive cells and FOXP3 positive cells. Images were taken at 20X scanning
magnification.
doi:10.1371/journal.pone.0022047.g005
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SPARC expression
The pathological features of CRC, T-cell markers and SPARC
expression are listed in Table 2. The density of CD8
+, CD45RO
+
and FOXP3
+ cells in tumour tissue inversely correlated with AJCC
stage (consistent with the TMA data; Figure 4A), whilst no
significant correlation between SPARC expression and AJCC was
observed (also consistent with the TMA data Figure 3B). CD8
+
and CD45RO
+ expression inversely correlated to perineural
invasion, and directly correlated with lymphocytic response and
microsatellite instability.
Adjuvant chemotherapy
TMA collection occurred from 1990-96 and prior to 1994
chemotherapy was not routinely given for CRC. Of the patients in
this cohort, 8% of stage II and 44% of stage III patients received
Figure 6. T cell density and disease outcome. When dividing the patients into good and poor disease outcome, FOXP3 expression was
significantly greater in patients with a good disease outcome in (A) stage II CRC but not in (B) stage III CRC. Similarly, CD8 was also significantly
greater in patients with a good disease outcome in (C) stage II CRC but not in (D) stage III, as with CD45RO in (E) stage II and (F) stage III. Each dot
represents one patient and the bars represent the median value 6 SE.
doi:10.1371/journal.pone.0022047.g006
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were compared between patients who had, and had not, received
adjuvant chemotherapy post-surgical resection (Table 3). The
ratio of SPARC to vimentin expression was significantly greater in
patients with stage III CRC, who had not received adjuvant
therapy (p=0.01), while in patients with stage II CRC, FOXP3
+
cell density was significantly greater in those patients who had
received adjuvant therapy compared to those who had not
(p=0.04).
Discussion
Cell migration or invasion through the basement membrane
and distant spread via the lymphatic or vascular systems are
inherent characteristics of malignant disease and have a significant
impact on disease outcome[3]. These migratory processes require
the differential regulation of adhesive and anti-adhesive molecules,
and it has been suggested that SPARC may play a key role in the
initial processes of tumour invasiveness and ECM modulation is
due to its anti-adhesive properties. Treg cells may also contribute
to malignant disease by suppressing local anti-tumour immune
responses within the tumour microenvironment[29,30]. The
presence of high numbers of FOXP3-positive T cells has been
associated with a higher risk of disease recurrence and poor overall
survival of patients with solid tumours[29]. AJCC disease staging is
based on histological evidence of infiltration and metastasis, it was,
therefore, hypothesised that SPARC and FOXP3 expression may
be associated with primary CRC disease stage and cancer specific
survival.
This study observed a higher ratio of SPARC to vimentin in
CRCs, regardless of disease stage, than in control tissue, suggesting
a role for SPARC in colorectal carcinogenesis. Stages II, III and
IV CRC all had significantly higher SPARC expression than stage
I, however, there were no significant differences observed between
stages II, III or IV CRC, indicating that although SPARC
expression was higher in the intermediate and most advanced
Figure 8. Overall survival. Kaplan-Meier survival curves were derived to show high and low marker levels in relation to survival. (A) High SPARC
levels significantly correlated with better long-term survival. (B) High FOXP3 levels also significantly correlated with better long-term survival.
Although high (C) CD8 and (D) CD45RO expression levels were associated with better long-term survival, the separation and significance between
the curves were not as great.
doi:10.1371/journal.pone.0022047.g008
Figure 7. Cancer-specific survival. The mean SPARC and FOXP3 expression in the primary tumour was measured and correlated with disease
recurrence. The number of patients with or without disease recurrence at each time point is displayed below each graph. (A) SPARC expression in
stage II CRC. Patients without disease recurrence had significantly higher SPARC levels at all time point up to 60 months and for most points up to
138 months compared to those patients who suffered a disease recurrence. The overall SPARC expression was significantly different between the two
groups (p,0.0001). (B) SPARC expression in stage III CRC. SPARC expression was significantly higher in patients without disease recurrence from 84
months and beyond. SPARC was also significantly different between the two groups (p,0.0001). (C) FOXP3 expression in stage II CRC. Higher
FOXP3 levels was also significantly associated with less disease recurrence as with (D) FOXP3 expression in stage III CRC, however, the differences
were not as marked as in stage II CRC. FOXP3 expression was significantly different between the two groups in both stage II and III (p,0.0001). Each
data point represented the mean SPARC or FOXP3 expression level at each time point. (*) p,0.05, (**) p,0.01.
doi:10.1371/journal.pone.0022047.g007
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has previously been suggested[6,18,31]. These studies, undertaken
in human gastric carcinoma[6], CRC[31] breast[18] and
oesophageal cancer[32], identified that SPARC was a poor
prognosis marker, and was associated with more aggressive and
highly metastatic tumours. Our findings, however, demonstrated
that higher levels of SPARC expression in the primary CRC was
associated with a good disease outcome and a better long-term
cancer-free survival .60 months in both stage II and III CRC,
and conversely that lower SPARC expression was associated with
a more advanced clinical disease stage.
Our findings are consistent with the observation that reduced
SPARC levels in primary CRC xenografts can increase tumour
resistance to radiation and chemotherapeutic agents[33]. Radio-
sensitivity and response to 5-fluorouracil and irinotecan in the
mouse xenografts, however, was able to be restored by the re-
expression of SPARC, while the overexpression of SPARC in
CRC xenografts enhanced tumour sensitivity to radiation and
chemotherapy[33]. Although prior to 1994 chemotherapy was not
routine, in our study, which collected samples from 1990 to 1996,
the majority of patients with stage III CRC and higher SPARC
expression did not receive chemotherapy. This suggests the
possibility that, not only is SPARC capable of sensitising CRC
cells to chemotherapy[33,34], but higher SPARC expression may
be associated with other clinical features that the clinician thinks
makes the tumour less aggressive and thus not require adjunctive
therapy.
SPARC may be potentially anti-tumorigenic through the
induction of a microenvironment that is non-permissive to tumour
progression[35]. Chlenski et al, demonstrated that enhanced
SPARC expression in mouse xenografts through transfected cells,
resulted in a decrease in smooth muscle actin expression, as well as
impaired xenograft growth, inhibition of angiogenesis and more
tumour stroma compared to wild-type and vector-control 293
xenografts[35]. Co-culturing of the SPARC-transfected cells with
wild-type or vector-control xenografts also resulted in fewer
activated fibroblasts that were unable to produce enough ECM to
support tumour growth. By altering the composition of the tumour
stroma through the inhibition of vascular cells, recruitment of host
fibroblasts and prevention of fibroblast activation, it was suggested
that SPARC may play a role in ‘‘normalising’’ the tumour stroma,
leading to a microenvironment that is not supportive of tumour
growth and progression[35].
In concordance with earlier reports that tumour infiltrating
FOXP3
+, CD8
+ and CD45RO
+ T cells are associated with better
patient survival[8,10,28,36], our study confirms the importance of
T cell density as a prognostic marker in CRC. Important findings
of this study, however, are that FOXP3 inversely correlated with
CRC disease progression and high FOXP3 expression levels
specifically correlated with a good disease outcome in stage II
CRC. FOXP3 expression was also higher in a good, compared to
poor, disease outcome in stage III CRC, but this was not
significantly different. A major difference between stage II and III
cancers, however, is that stage II cancers are localised to the gut,
whilst stage III cancers have lymphatic spread with the tumours
taking on a metastatic phenotype within a pro-inflammatory
microenvironment. Under these conditions, Tregs fail to inhibit
tumour progression and may even contribute to a T-helper (Th)-
17 driven pro-carcinogenic process[37]. This may potentially
explain why differences between good and poor disease outcome
in stage III CRC did not reach statistical significance. FOXP3 was
also noted to be associated with low disease recurrence and better
long-term survival. This suggests that the levels of FOXP3
expression, as for SPARC, in the patient’s primary tumour may
play an important prognostic role that could assist in distinguishing
between stage II cancers that would, and would not, benefit from
post-operative adjuvant chemotherapy. Being able to predict
disease outcome from the primary tumour would allow for the
development of specific treatment regimes to suit each individual
patient.
In most solid tumours including melanoma[38], breast[26],
ovarian[39], hepatocellular[40] and pancreatic cancer[41], Tregs
have been implicated in tumour progression because of their
primary role as a suppressor of cytotoxic T cells and the host’s
protective anti-tumour inflammatory responses. The work that is
presented in this study, however, demonstrates the opposite, where
Treg levels are inversely correlated with disease stage and is
associated with good disease outcomes. One study that supports
our findings postulated that the risk of CRC is greatest when
Table 1. (A) Univariate survival analysis for SPARC, FOXP3,
CD8 and CD45RO in CRC tissue from patients with stage II and
III CRC.
A. Univariate survival analysis for SPARC, FOXP3, CD8 and CD45RO in
CRC tissue from patients with Stage II and III CRC
Marker OR 95% CI p value
SPARC 0.96 0.94 to 0.980.0001
FOXP3 0.86 0.74 to 1.0 0.05
CD8 0.83 0.72 to 0.960.12
CD45RO 0.84 0.72 to 0.970.017
NB: Univariate analysis, COX proportional hazards regression.
B. Multivariate analysis for significant prognostic indicators in CRC
tissue from patients with Stage II and III CRC
Marker OR 95% CI p value
SPARC 0.96 0.94 to 0.980.0001
FOXP3 0.90 0.76 to 1.0 0.219
CD8 0.85 0.71 to 1.0 0.0.58
CD45RO 1.00 0.84 to 1.2 0.916
Combination I
SPARC 0.96 0.94 to 0.980.0001
FOXP3 0.85 0.74 to 0.990.0034
Overall significance 0.0001
Combination II
SPARC 0.96 0.94 to 0.980.0001
CD8 0.82 0.71 to 0.950.01
Overall significance 0.0001
Combination III
FOXP3 0.92 0.77 to 1.1 0.31
CD8 0.87 0.73 to 1.0 0.10
CD45RO 0.96 0.80 to 1.1 0.65
Overall significance 0.065
High expression levels of all markers significantly predict patient survival. (B)
Multivariate analysis for significant prognostic indicators in CRC
tissue from patients with stage II and III CRC. All four markers combined
did not improve the predictive value over individual markers. The combination
of SPARC and FOXP3, or SPARC and CD8, predicted survival better than all four
markers together, or the combination of FOXP3, CD8 and CD45RO, but no
combination improved on the predictive sensitivity of SPARC used alone.
NB: COX proportional hazards regression model. Abbreviations: CRC –
colorectal cancer, OR – odds ration, 95% CI– 95% confidence interval.
doi:10.1371/journal.pone.0022047.t001
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immunity are unable to restore and support systemic homo-
estasis[37]. The investigators demonstrated that the ability of
Tregs to inhibit or suppress cancer was highly dependent upon the
type of gut bacteria and IL-10. Individuals with a weakened IL-10
and Treg-mediated inhibitory loop are highly susceptible to the
carcinogenic consequences of gut bacteria-induced inflammation
and show more frequent inflammation-associated cancers[37]. A
functional link between chronic inflammation and cancer has long
been suspected, but the crucial molecular pathways that permit
communication between cancer cells and inflammatory cell
infiltrates largely remain unknown. These concepts are supported
by the above study but further functional studies into the role
Tregs play in the anti-tumour response are still required in order
to explain these observed associations with prognosis and disease
recurrence.
In conclusion, this present study confirmed that CD8 and CD45
correlate with CRC disease stage and outcome. It is, however, the
first to report on the prognostic significance of SPARC and
FOXP3 in distinguishing between good and poor disease outcome
in stage II CRC. Furthermore, multivariate analysis demonstrated
Table 2. Correlation of CRC pathology with T-cell density and SPARC expression.
Univariate analysis for Pathological features vs. SPARC, FOXP3, CD8 and CD45RO expression from patients with Stage II and III CRC
Features Correlation coefficient n p value
SPARC
AJCC 20.02 345 NS
Site, distal vs. proximal 0.03 336 NS
Grade, poor vs. well/moderate 20.05 258 NS
Vascular invasion, yes vs. no 20.04 299 NS
Lymphatic invasion, yes vs. no 0.02 198 NS
Perineural invasion, yes vs. no 20.009 288 NS
Lymphatic response, yes vs. no 0.00 331 NS
Microsatelite instability, yes vs. no 20.04 330 NS
FOXP3
AJCC 20.04 329 0.0002
Site, distal vs. proximal 20.05 321 NS
Grade, poor vs. well/moderate 20.38 245 0.02
Vascular invasion, yes vs. no 20.06 286 NS
Lymphatic invasion, yes vs. no 0.24 189 NS
Perineural invasion, yes vs. no 20.41 275 NS
Lymphatic response, yes vs. no 20.06 316 NS
Microsatelite instability, yes vs. no 0.11 315 NS
CD8
AJCC 20.64 316 ,0.0001
Site, distal vs. proximal 0.13 310 NS
Grade, poor vs. well/moderate 20.19 232 NS
Vascular invasion, yes vs. no 0.01 272 NS
Lymphatic invasion, yes vs. no 20.05 174 NS
Perineural invasion, yes vs. no 20.69 261 0.01
Lymphatic response, yes vs. no 0.39 303 0.02
Microsatelite instability, yes vs. no 0.70 301 0.0001
CD45RO
AJCC 20.61 33 ,0.0001
Site, distal vs. proximal 0.18 325 NS
Grade, poor vs. well/moderate 20.14 250 NS
Vascular invasion, yes vs. no 20.12 289 NS
Lymphatic invasion, yes vs. no 0.10 193 NS
Perineural invasion, yes vs. no 20.70 278 0.002
Lymphatic response, yes vs. no 0.26 319 0.055
Microsatelite instability, yes vs. no 0.59 318 ,0.05
This table illustrates the correlation between different CRC pathological features and T-cell density or SPARC expression using univariate analysis.
Abbreviations: n- number, NS–not significant, AJCC – American Joint Committee on Cancer.
doi:10.1371/journal.pone.0022047.t002
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CD45RO, whilst SPARC had the strongest prognostic value of all
four markers measured. Although further studies are required
before these markers can be employed, the present results suggest
that assessment of SPARC and FOXP3 expression in tumour
tissue should improve the prognostic classification of stage II and
III CRC.
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